Loading
A phase 2 trial of Capecitabine in brain and spinal cord tumours, run by Biostar Pharma, Inc., now recruiting.
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases is a phase 2 interventional study registered as NCT06764940 by Biostar Pharma, Inc., with 120 participants planned, started 2025-07-14 and due to reach its primary completion in 2027-01-15. Interventions recorded: Utidelone and Utidelone in combination with capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biostar Pharmaceuticals, Utidelone, Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/